ADVFN US – Market Content Editor

Axsome Therapeutics Inc. (NASDAQ:AXSM) reported fourth-quarter results that topped analyst forecasts, although the company’s shares fell 2.03% in premarket trading following the announcement. The biopharmaceutical company posted a quarterly loss of $0.56 per share, outperforming the consensus expectation for a loss of $0.73 per share. Revenue for the quarter came in at $196.0 million, exceeding…

ImmunityBio, Inc. (NASDAQ:IBRX), a commercial-stage immunotherapy company, disclosed significant financial and operational progress for 2025 in a newly filed SEC Form 8-K, highlighting sharp revenue growth, expanding product approvals and advancing international partnerships. Financial Performance The company reported full-year net product revenue of $113 million for 2025, representing an approximately 700% increase compared with the…

Tian Ruixiang Holdings Ltd (NASDAQ:TIRX) said it is in advanced, final-stage discussions regarding a potential strategic business combination with a leading insurance technology company operating across the Asia-Pacific region. The company also confirmed it continues to advance its previously announced strategy to acquire Bitcoin (BTC), part of a broader effort aimed at strengthening long-term shareholder…

Fortress Biotech, Inc. (NASDAQ:FBIO) said its majority-owned subsidiary Cyprium Therapeutics has signed a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205 million, marking a significant monetization event following the recent FDA approval of ZYCUBO®. The voucher was granted after the U.S. Food and Drug Administration approved…

Gossamer Bio (NASDAQ:GOSS) shares dropped roughly 80% on Monday after the company announced that its investigational therapy seralutinib failed to achieve the primary endpoint in the Phase 3 PROSERA study targeting pulmonary arterial hypertension (PAH). The trial reported a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of 13.3 meters at Week 24, with a p-value…

Atomera Incorporated (NASDAQ:ATOM) shares dropped 15% on Monday after the company disclosed plans for a $25 million registered direct offering of common stock. The semiconductor materials and technology licensing firm said it has entered into a securities purchase agreement with institutional investors to sell 5,000,000 shares priced at $5.00 each. The transaction is expected to…

Arcellx Inc. (NASDAQ:ACLX) shares soared 78.3% in premarket trading Monday after Gilead Sciences (NASDAQ:GILD) revealed plans to acquire the biotechnology company in a transaction valuing its equity at approximately $7.8 billion. Under the terms of the agreement, Arcellx shareholders will receive $115 per share in cash along with a contingent value right (CVR) worth up…

Reliance Global Group Inc. (NASDAQ:EZRA) shares surged 28% in premarket trading Monday after the company completed its acquisition of Enquantum Ltd., a developer of post-quantum cryptography technology. The transaction marks the first platform acquisition under Reliance’s EZRA Scale51 operating framework and creates a pathway for the company to obtain majority ownership of Enquantum. As part…

VenHub Global (NASDAQ:VHUB) shares climbed about 20% on Monday morning after the company unveiled new self-diagnostic features for the robotics powering its autonomous retail stores. The automated retail technology firm said key robotic components — including robotic arms, adaptive storage bins and smart refrigeration units — are now equipped with systems capable of detecting operational…

Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) surged about 33% to $7.68 in premarket trading Monday after the company announced late Friday that the U.S. Food and Drug Administration had approved its drug Bysanti, sparking strong after-hours gains. The sharp move shifted investor focus to whether the rally can hold through regular trading, particularly after the stock…